

- Adkins, R.B., Chapman, W.C., Reddy, V.S., 2000. EMBRYOLOGY, ANATOMY, AND SURGICAL APPLICATIONS OF THE EXTRAHEPATIC BILIARY SYSTEM. *Surg. Clin. North Am.* 80, 363–379. [https://doi.org/10.1016/S0039-6109\(05\)70410-2](https://doi.org/10.1016/S0039-6109(05)70410-2)
- Agarwal, A.K. *et al.* (2007) ‘Biliary obstruction in gall bladder cancer is not sine qua non of inoperability’, *Annals of Surgical Oncology*, 14(10), pp. 2831–2837. Available at: <https://doi.org/10.1245/s10434-007-9456-y>.
- Ahmed, A., Shahriar, S., Shimu, F., Alam, S.S.U., Sarker, R.D., 2020. Prognostic Relevance of Significantly Raised CA 19-9 with Choledocholithiasis to Malignant Pathologies of HBS: An Early Experience in Dept. of Hepatobiliary Surgery at ShSMCH, Dhaka. *J. Shaheed Suhrawardy Med. Coll.* 11, 119–123. <https://doi.org/10.3329/jssmc.v11i2.48962>
- Copelan, A., Kapoor, B.S., 2015. Choledocholithiasis: Diagnosis and Management. *Tech. Vasc. Interv. Radiol.* 18, 244–255. <https://doi.org/10.1053/j.tvir.2015.07.008>
- Corti, A., Belcastro, E., Dominici, S., Maellaro, E., Pompella, A., 2020. The dark side of gamma-glutamyltransferase (GGT): Pathogenic effects of an ‘antioxidant’ enzyme. *Free Radic. Biol. Med.* 160, 807–819. <https://doi.org/10.1016/j.freeradbiomed.2020.09.005>
- Freitas, M.L., 2006. Choledocholithiasis: Evolving standards for diagnosis and management. *World J. Gastroenterol.* 12, 3162. <https://doi.org/10.3748/wjg.v12.i20.3162>
- Groot Koerkamp, B., Fong, Y., 2014. Outcomes in biliary malignancy: Surgery for Biliary Cancer. *J. Surg. Oncol.* 110, 585–591. <https://doi.org/10.1002/jso.23762>
- Gu, W., Tong, Z., 2020. Serum Carbohydrate Antigen 199 as a Biomarker for Evaluating Patients with Choledocholithiasis. *Gastroenterol. Res. Pract.* 2020, 1–5. <https://doi.org/10.1155/2020/2739612>
- Guarino, M., Cossiga, V., Morisco, F., 2020. The interpretation of liver function tests in pregnancy. *Best Pract. Res. Clin. Gastroenterol.* 44–45, 101667. <https://doi.org/10.1016/j.bpg.2020.101667>
- Liu, W., Liu, Q., Wang, W., Wang, P., Chen, J., Hong, T., Zhang, N., Li, B., Qu, Q., He, X., 2018. Differential diagnostic roles of the serum CA19-9, total bilirubin (TBIL) and the ratio of CA19-9 to TBIL for benign and malignant. *J. Cancer* 9, 1804–1812. <https://doi.org/10.7150/jca.25093>
- Moshref, L.H., Mandili, R.A., Almaghrabi, M., Abdulwahab, R.A., Alosaimy, R.A., Miro, J., 2021. Elevation of CA 19-9 in Mirizzi Syndrome in the Absence of Malignancy: A Case Report. *Am. J. Case Rep.* 22. <https://doi.org/10.12659/AJCR.931819>
- Rosida, A., 2016. Pemeriksaan Laboratorium Penyakit Hati. *Berk. Kedokt.* 12, 123. <https://doi.org/10.20527/jbk.v12i1.364>
- Sauvanet, A. *et al.* (2015) ‘Severe Jaundice Increases Early Severe Morbidity and Decreases Long-Term Survival after Pancreaticoduodenectomy for Pancreatic Adenocarcinoma’, *Journal of the American College of Surgeons*, 221(2), pp. 380–389. Available at: <https://doi.org/10.1016/j.jamcollsurg.2015.03.058>.
- Sharma, U., Pal, D., Prasad, R., 2014. Alkaline Phosphatase: An Overview. *Indian J. Clin. Biochem.* 29, 269–278. <https://doi.org/10.1007/s12291-013-0408-y>
- Shrotriya, S., Walsh, D., Nowacki, A.S., Lorton, C., Aktas, A., Hullihen, B., Benanni-Baiti, N., Hauser, K., Ayvaz, S., Estfan, B., 2018. Serum C-reactive protein is an important and powerful prognostic biomarker in most adult solid tumors. *PLOS ONE* 13, e0202555. <https://doi.org/10.1371/journal.pone.0202555>
- Song, X.-H., Liu, K., Yang, S.-J., Zhang, W.-H., Chen, X.-L., Zhao, L.-Y., Chen, X.-Z., Yang, K., Zhou, Z.-G., Hu, J.-K., 2020. Prognostic Value of Changes in Preoperative and

- Postoperative Serum CA19-9 Levels in Gastric Cancer. *Front. Oncol.* 10, 1432. <https://doi.org/10.3389/fonc.2020.01432>
- Song, J.G. *et al.* (2009) 'Baroreflex sensitivity is impaired in patients with obstructive jaundice', *Anesthesiology*, 111(3), pp. 561–565. Available at: <https://doi.org/10.1097/ALN.0b013e3181adf49f>.
- Stinton, L.M., Shaffer, E.A., 2012. Epidemiology of Gallbladder Disease: Cholelithiasis and Cancer. *Gut Liver* 6, 172–187. <https://doi.org/10.5009/gnl.2012.6.2.172>
- the SAGES Guidelines Committee, Narula, V.K., Fung, E.C., Overby, D.W., Richardson, W., Stefanidis, D., 2020. Clinical spotlight review for the management of choledocholithiasis. *Surg. Endosc.* 34, 1482–1491. <https://doi.org/10.1007/s00464-020-07462-2>
- Tran, T.B. *et al.* (2017) 'Gallbladder Cancer Presenting with Jaundice: Uniformly Fatal or Still Potentially Curable?', *Journal of Gastrointestinal Surgery*, 21(8), pp. 1245–1253. Available at: <https://doi.org/10.1007/s11605-017-3440-z>.
- Vakili, K., Pomfret, E.A., 2008. Biliary Anatomy and Embryology. *Surg. Clin. North Am.* 88, 1159–1174. <https://doi.org/10.1016/j.suc.2008.07.001>
- Wang, Q., Shu, X., Dong, Y., Zhou, J., Teng, R., Shen, J., Chen, Y., Dong, M., Zhang, W., Huang, Y., Xie, S., Wei, Q., Zhao, W., Chen, W., Yuan, X., Qi, X., Wang, L., 2017. Tumor and serum gamma-glutamyl transpeptidase, new prognostic and molecular interpretation of an old biomarker in gastric cancer. *Oncotarget* 8, 36171–36184. <https://doi.org/10.18632/oncotarget.15609>
- Wilkins, T., Agabin, E., Varghese, J., Talukder, A., 2017. Gallbladder Dysfunction: Cholecystitis, Choledocholithiasis, Cholangitis, and Biliary Dyskinesia. *Prim. Care Clin. Off. Pract.* 44, 575–597. <https://doi.org/10.1016/j.pop.2017.07.002>
- Wills, C., 2021. Give doctors the regulatory regime they deserve. *Br. J. Hosp. Med.* 82, 1–2. <https://doi.org/10.12968/hmed.2021.0352>
- Xu, M., Sethi, A., 2015. Diagnosing Biliary Malignancy. *Gastrointest. Endosc. Clin. N. Am.* 25, 677–690. <https://doi.org/10.1016/j.giec.2015.06.011>
- Zhang, L., Lv, Y., Xu, A.-M., Wang, H., 2019. The prognostic significance of serum gamma-glutamyltransferase levels and AST/ALT in primary hepatic carcinoma. *BMC Cancer* 19, 841. <https://doi.org/10.1186/s12885-019-6011-8>